CO-GLEN SITE REPRESENTATIVE
Zeinab has a Master’s in Biotechnology from McGill and is currently in her 4th year of PhD in the Experimental Medicine Department. Her PhD project focuses on a novel drug for the treatment of glioblastoma (GBM). GBM is the most aggressive type of brain tumour in adults. Patients diagnosed with GBM approximately live for 12-15 months, despite combined treatments including surgery followed by radiation therapy and chemotherapy. Zeinab is passionate about her research because it gives her hope to think that one day her work might help improve a cancer patient’s life expectancy.
As co-Glen representatives, Zeinab & Sanket will communicate all EMGSS-related information to Experimental Medicine students residing at the RI-MUHC (Glen) site. They will also assist the VP Internal with Glen related activities (social, academic or otherwise). Lastly, they would connect with the ExMed students at the Glen site and raise their issues, if any, to the EMGSS.